NanoString Technologies (NanoString Technologies) Debt-to-Equity : -4.90 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is NanoString Technologies Debt-to-Equity?

NanoString Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $5.6 Mil. NanoString Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $242.1 Mil. NanoString Technologies's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-50.6 Mil. NanoString Technologies's debt to equity for the quarter that ended in Sep. 2023 was -4.90.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NanoString Technologies's Debt-to-Equity or its related term are showing as below:

NSTGQ' s Debt-to-Equity Range Over the Past 10 Years
Min: -15.63 Med: 1.19 Max: 140.8
Current: -4.9

During the past 13 years, the highest Debt-to-Equity Ratio of NanoString Technologies was 140.80. The lowest was -15.63. And the median was 1.19.

NSTGQ's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs NSTGQ: -4.90

NanoString Technologies Debt-to-Equity Historical Data

The historical data trend for NanoString Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoString Technologies Debt-to-Equity Chart

NanoString Technologies Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

1.58

1.09

0.66

1.42

5.47

NanoString Technologies Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															3.03	5.47	18.32	-11.59	-4.90

Competitive Comparison of NanoString Technologies's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, NanoString Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NanoString Technologies's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoString Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NanoString Technologies's Debt-to-Equity falls into.

NanoString Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NanoString Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.518	+	244.984)	/	45.814
	=	5.47

NanoString Technologies's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.578	+	242.124)	/	-50.566
	=	-4.90

NanoString Technologies (OTCPK:NSTGQ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NanoString Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NanoString Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NanoString Technologies (NanoString Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoString Technologies Inc (OTCPK:NSTGQ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0F1:Germany

Address

530 Fairview Avenue North, Seattle, WA, USA, 98109

Website

https://www.nanostring.com

NanoString Technologies Inc is engaged in the development, manufacturing and commercialization of instruments, consumables, and services for efficiently profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its core technology includes proprietary chemistries that enable the labeling and counting of single molecules. The firm uses its technology to develop tools for scientific and clinical research, primarily in the fields of genomics and proteomics. It offers two product platforms such as nCounter Analysis System or nCounter, and GeoMx Digital Spatial Profiler or DSP system both include instruments, related consumables, and software. NanoString Technologies generates revenue from the sale of products and related services and collaborations.

Executives

Jonathan Todd Garland	officer: Chief Commercial Officer	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
K Thomas Bailey	officer: Chief Financial Officer	1618 STATION STREET, VANCOUVER A1 V6A 1B6
R Bradley Gray	director, officer: President and CEO	530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
William Young	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waite Charles P Jr	director, 10 percent owner	11023 NE 116TH STREET, KIRKLAND WA 98034
Gregory Norden	director	16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Elisha W Finney	director	C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Teresa M. Foy	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Joseph M Beechem	officer: SVP, Research & Development	530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
John D. Gerace	officer: Chief Commercial Officer	C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Kirk Malloy	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
J. Chad Brown	officer: SVP, Sales & Marketing	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Janet George	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Dana E. Rollison	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109